Levetiracetam Neuropsychiatric Adverse Effects Meta-Analysis, 33 Studies

33 studies published until March 14th, 2024, were included in a systematic review and meta-analysis of neuropsychiatric adverse effects associated with levetiracetam use in adults. The supplementary material, authored by figshare admin karger and last updated in May 2026, contains the analysis comparing levetiracetam to placebo and other anti-seizure medications. Results indicate a significantly higher risk of somnolence and fatigue compared to placebo.

Use Cases

• Validate the reported odds ratios for adverse effects like somnolence and fatigue based on the meta-analysis results.
• Identify the most frequently reported neuropsychiatric adverse effects (NPAEs) from the systematic review of 33 studies.
• Compare the risk profile of levetiracetam against placebo and other anti-seizure medications for specific outcomes like depression.

Strengths

• Includes a quantitative meta-analysis based on 7 randomized trials comparing levetiracetam to placebo and 4 trials comparing it to other ASMs.
• Provides specific odds ratios with 95% confidence intervals for key adverse effects like somnolence (OR 1.61) and asthenia (OR 1.48).
• Systematic review methodology with a defined literature search across PubMed, Embase, and Web of Science.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 464.7 KB file size suggests the dataset is limited to supplementary textual material rather than raw clinical data.

Provenance

Source

figshare admin karger

Collection Method

Systematic literature review and meta-analysis of published studies.

Time Range

Studies published until March 14th, 2024.

Freshness

Last updated 2026-05-14 07:55:31; freshness should be verified.

Geography

unknown